Xianju Pharmaceutical announced that the company recently received the “Drug Supplement Application Approval Notice” for ethinyl estradiol cycloproterone tablets approved and issued by the State Drug Administration. The drug passed the consistent evaluation of generic drug quality and efficacy. This medicine is mainly used to treat moderate to severe acne and/or hirsutism caused by androgen sensitivity in women of childbearing age. Passing evaluations is beneficial for consolidating and improving product competitiveness and accumulating follow-up evaluation experience, but drug research and development are affected by policies and markets, and there is uncertainty, which reminds investors to be aware of risks.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.